You are here

Launch Date Set for Eye Drug, Jetrea (Ocriplasmin)

First pharmacological treatment for vitreomacular adhesion (Jan. 4)

The U.S. launch date for Jetrea (ocriplasmin, ThromboGenics) has been set for January 14, 2013. Jetrea intravitreal injection is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion (VMA).

The drug’s recommended dose is 0.125 mg (0.1 mL) of the diluted solution administered by intravitreal injection to the affected eye once as a single injection. The U.S. price for a single-use glass vial is $3,950.

The FDA approved Jetrea in October 2012 as the first pharmacological agent for the treatment of symptomatic VMA. The approval was based on phase III data, which showed that Jetrea was significantly more effective than placebo in the treatment of symptomatic VMA (26.5% versus 10.1%, respectively; P

Symptomatic VMA is a progressive, sight-threatening condition that, when left untreated, often leads to retinal distortion, further deterioration in vision, and irreversible damage to eyesight.

Source: ThromboGenics; January 4, 2013.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
National Statistics Report Factors In Race, Ethnicity for the First Time